Oxidative modification of low-density lipoproteins in atherothrombosis

Acta Cardiologica

Volumn 53, Issue 5, 1998, Pages 253-260

  Holvoet, Paul ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE; APOLIPOPROTEIN B100; LOW DENSITY LIPOPROTEIN; LYSINE; MALONALDEHYDE; MYELOPEROXIDASE; PHOSPHOLIPASE; PROSTAGLANDIN; RADICAL; TROPONIN I;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ARTERY WALL; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HUMAN; LIPID PEROXIDATION; MUSCLE NECROSIS; OXIDATION; PROSTAGLANDIN SYNTHESIS; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION;

ANIMALS; CORONARY ARTERIOSCLEROSIS; CORONARY THROMBOSIS; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; OXIDATION-REDUCTION;

EID: 0032438431     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Gerrity RG. The role of the monocyte in atherogenesis. I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 1981; 103: 181-190.
2. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983; 52: 223-261.
3. Ross R. The pathogenesis of atherosclerosis: an update. N Engl J Med 1986; 314: 488-500.
4. Ross R. The pathogenesis of atherosclerosis: an update: a perspective for the 1990's. Nature 1993; 362: 801-809.
5. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69: 377-381.
6. Zeiher AM, Schachlinger V, Hohnloser SH, Saurbier B, Just H. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation 1994; 89: 2525-2532.
7. Esterbauer H, Jurgens G, Quehenberger Q, Koller E. (1987) Autooxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res 1987; 28: 495-509.
8. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984; 81: 3883-3887.
9. Parthasarathy S, Wieland E, Steinberg D. A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci USA 1989; 86: 1046-1050.
10. Ravalli S, Marboe CC, D'Agati VD, Michler RE, Sigal E, Cannon PJ. Immunohistochemical demonstration of 15-lipoxygenase in transplant coronary artery disease. Arterioscler Thromb Vasc Biol 1995; 15: 340-348.
11. Menschikowski M, Kasper M, Lattke P, Schiering A, Schiefer S, Stockinger H, Jaross W. Secretory group II phospholipase A2 in human atherosclerotic plaques. Atherosclerosis 1995; 118: 173-181.
12. Aviram M, Maor I. Phospholipase D-modified low density lipoprotein is taken up by macrophages at increased rate. A possible role for phosphatidic acid. J Clin Invest 1993; 91: 1942-1952.
13. Savenkova ML, Mueller DM, Heinecke JW. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. J Biol Chem 1994; 269: 20394-20400.
14. 2-isoprostanes) in plasma of low density-lipoprotein exposed to oxidative stress in vitro. J Clin Invest 1994; 93: 998-1004.
15. Haberland ME, Fong D, Cheng L. Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 1988; 241: 215-218.
16. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler JS, Witztum L, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 84: 1086-1095.
17. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J, Lesaffre E, Vanrenterghem Y, Collen D. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost 1996; 76: 663-669.
18. Holvoet P, Perez G, Zhao Z, Brouwers E, Bernar H, Collen D. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 1995; 95: 2611-2619.
19. Holvoet P, Collen D. βVLDL hypercholesterolemia relative to LDL hypercholesterolemia is associated with higher levels of oxidized lipoproteins and a more rapid progression of coronary atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 1997; 17: 2376-2382.
20. Holvoet P, Theilmeier G, Shivalkar B, Flameng W, Collen D. LDL hypercholesterolemia is associated with accumulation of oxidized LDL, atherosclerotic plaque growth and compensatory vessel enlargement coronary arteries of miniature pigs. Arterioscler Thromb Vasc Biol 1998; 18: 415-422.
21. Shimano H, Yamada N, Ishibashi S, Mokuno H, Mori N, Gotoda T, Harada K, Akanuma Y, Murase T, Yazaki Y, Takaku F. Oxidation-labile subfraction of human low density lipoprotein isolated by ion-exchange chromatography. J Lipid Res 1991; 32: 763-773.
22. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, Esterson M, Fogelmann AM. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin invest 1990; 85: 1260-1266.
23. Lavy A, Brook GJ, Dankner G, Ben-Amotz A, Aviram M. Enhanced in vitro oxidation of plasma lipoproteins derived from hypercholesterolemic patients. Metabolism 1991; 40: 794-799.
24. Chait A, Brazg RL, Tribble DL, Krauss RM. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993; 94: 350-356.
25. Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993; 34: 295-308.
26. O'Keefe JH Jr, Lavie CJ Jr, McCallister BD. Insights into the pathogenesis and prevention of coronary artery disease. Mayo Clin Proc 1995; 70: 69-79.
27. Holvoet P, Stassen J-M, Van Cleemput J, Collen D, Vanhaecke J. Oxidised low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18: 100-107.
28. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidised LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998; 98: 1487-1494.
29. Woolf N. Endothelial alterations in atherogenesis. In Pathology of atherosclerosis (Woolf N, ed), Butterworth and Company, London, 1982; pp 261-285.
30. Holland JA, Pritchard KA, Rogers NJ, Stemerman MB. Atherogenic levels of low-density lipoprotein increase endocytotic activity in cultured human endothelial cells. Am J Pathol 1992; 140: 551-558.
31. Joris I, Zand T, Nunnari JJ, Krolikowski FJ, Majno G. Studies on the pathogenesis of atherosclerosis. I. Adhesion of mononuclear cells in the aorta of hypercholesterolemic rats. Am J Pathol 1983; 113: 341-358.
32. Carlos TM, JM. Membrane proteins involved in phagocyte adherence to endothelium. Immunol Rev 1990; 114: 5-28.
33. Ylä-Herttuala S, Lipton BA, Rosenfeld ME, Särkioja T, Yoshimura T, Leonard EJ, Witztum JL, Steinberg D. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991; 88: 5252-5256.
34. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, Lusis AJ. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990; 344: 254-257.
35. Ishibashi S, Inaba T, Shimano H, Harada K, Inoue I, Mokuno H, Mori N, Gotoda T, Takaku F, Yamada N. Monocyte colony-stimulating factor enhances uptake and degradation of acetylated low density lipoproteins and cholesterol esterification in human monocyte-derived macrophages. J Biol Chem 1990; 265: 14109-14117.
36. Stiko-Rahm A, Hultgardh-Nilsson A, Regnstrom J, Hamsten A, Nilsson J. Native and oxidized LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human smooth muscle cells. Arterioscler Thromb 1992; 12: 1099-1109.
37. Lindner V, Lappi DA, Baird A, Majack RA, and Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 1991; 68: 106-113.
38. Chin JH, Azhar S, Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992; 89: 10-18.
39. Boulanger CM, Tanner FC, Bea ML, Hahn AW, Werner A, Luscher TF. Oxidised low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res 1992; 70: 1191-1197.
40. Weisser B, Locher R, Mengden T, Vetter W. Oxidation of low density lipoprotein enhances its potential to increase intracellular free calcium concentration in vascular smooth muscle cells. Arterioscler Thromb 1992; 12: 231-236.
41. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1990; 335: 1109-1113.
42. Tselepis AD, Dentan C, Karabina SA, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 1995; 15: 1764-1773.
43. Gawaz M, Neumann FJ, Ott I, Schiessler A, Schomig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996; 93: 229-237.
44. Diacovo TG, Puri KD, Warnock RA, Springer TA, von Andrian UH. Platelet-mediated lymphocyte delivery to high endothelial venules. Science 1996; 273: 252-255.
45. Lehr HA, Olofsson AM, Carew TE, Vajkoczy P, von Andrian UH, Hubner C, Berndt MC, Steinberg D, Messmer K, Arfors KE. P-selectin mediates the interaction of circulating leukocytes with platelets and microvascular endothelium in response to oxidized lipoprotein in vivo. Lab Invest 1994; 71: 380-386.
46. Farber HW, Barnett HF. Differences in prostaglandin metabolism in cultured aortic and pulmonary arterial endothelial cells exposed to acute and chronic hypoxia. Circ Res 1991; 68: 1446-1457.
47. Lynch SM, Morrow JD, Roberts LJ 2nd, Frei B. Formation of non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro. J Clin Invest 1994; 93: 998-1004.
48. Morrow JD, Awad JA, Boss HJ, Blair IA, Roberts LJ 2nd. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci USA 1992; 89: 10721-10725.
49. Morrow JD, Roberts LJ 2nd. The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol 1996; 51: 1-9.
50. Laskey RE, Mathews WR. Nitric oxide inhibits peroxynitrite-induced production of hydroxyeicosatetraenoic acids and F2-isoprostanes in phosphatidylcholine liposomes. Arch Biochem Biophys 1996; 330: 193-198.
51. Pratico D, FitzGerald GA. Generation of 8-epiprostaglandin F2alpha by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. J Biol Chem 1996; 271: 8919-8924.
52. Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Sumiyoshi A. Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb Haemost 1996; 75: 389-392.
53. Lewis JC, Bennett Cain AL, DeMars CS, Doellgast GJ, Grant KW, Jones NL, Gupta M. Procoagulant activity after exposure of monocyte-derived macrophages to minimally oxidized low density lipoprotein. Co-localization of tissue factor antigen and nascent fibrin fibers at the cell surface. Am J Pathol 1995; 147: 1029-1040.
54. Abumiya T, Yamaguchi T, Terasaki T, Kokawa T, Kario K, Kato H. Decreased plasma tissue factor pathway inhibitor activity in ischemic stroke patients. Thromb Haemost 1995; 74: 1050-1054.
55. Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, Courtman DW, Ezban M, Ellis SG, Topol EJ. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995; 92: 3041-3050.
56. Lesnik P, Dentan C, Vonica A, Moreau M, Chapman MJ. Tissue factor pathway inhibitor activity associated with LDL is inactivated by cell- and copper-mediated oxidation. Arterioscler Thromb Vasc Biol 1995; 15: 1121-1130.
57. Weis JR, Pitas RE, Wilson BD, Rodgers GM. Oxidised low-density lipoprotein increases cultured human endothelial cell tissue factor activity and reduces protein C activation. Faseb J 1991; 5: 2459-2465.
58. Loskutoff DJ, van Aken BE, Seiffert D. Abnormalities in the fibrinolytic system of the vascular wall associated with atherosclerosis. Ann N Y Acad Sci 1995; 748: 177-183; discussion 183-184.
59. Robbie LA, Booth NA, Brown AJ, Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol 1996; 16: 539-545.
60. Shireman PK, McCarthy WJ, Pearce WH, Patterson BK, Shively VP, Cipollone M, Tamarina N, Verrusio EN, Kwaan HC. Elevated levels of plasminogen-activator inhibitor type 1 in atherosclerotic aorta. J Vasc Surg 1996; 23: 810-817.
61. Padro T, Emeis JJ, Steins M, Schmid KW, Kienast J. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol 1995; 15: 893-902.
62. Kugiyama K, Sakamoto T, Misumi I, Sugiyama S, Ohgushi M, Ogawa H, Horiguchi M, Yasue H. Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res 1993; 73: 335-343.